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Abstract
Leber’s hereditary optic neuropathy (LHON) has traditionally been considered a disease causing severe and permanent
visual loss in young adult males. In nearly all families with LHON it is associated with one of three pathogenic mitochondrial
DNA (mtDNA) mutations, at bp 11778, 3460 or 14484. The availability of mtDNA confirmation of a diagnosis of LHON
has demonstrated that LHON occurs with a wider range of age at onset and more commonly in females than previously
recognised. In addition, analysis of patients grouped according to mtDNA mutation has demonstrated differences both in
the clinical features of visual failure and in recurrence risks to relatives associated with each of the pathogenic mtDNA
mutations. Whilst pathogenic mtDNA mutations are required for the development of LHON, other factors must be
reponsible for the variable penetrance and male predominance of this condition. Available data on a number of hypotheses
including the role of an additional X-linked visual loss susceptibility locus, impaired mitochondrial respiratory chain activity,
mtDNA heteroplasmy, environmental factors and autoimmunity are discussed. Subacute visual failure is seen in association
with all three pathogenic LHON mutations. However, the clinical and experimental data reviewed suggest differences in the
phenotype associated with each of the three mutations which may reflect variation in the disease mechanisms resulting in this
common end-point. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The ¢rst descriptions of subacute, bilateral visual
loss in young adult males date back to the early 19th
century but the majority of these are poorly docu-
mented. In reviewing these and providing a descrip-
tion of three brothers a¡ected by the same disease,
Von Graefe (1858) recognised this as a form of he-
reditary optic neuropathy [1]. However, Leber (1871)
was the ¢rst to provide an accurate description of the
clinical features and inheritance of the condition that
now bears his name [2]. He reported four families
which included members who developed subacute,
sequential visual failure. He noted that the disease
was hereditary, could be transmitted by an unaf-
fected mother and that more males were a¡ected
than females. Further descriptions of families with
the same phenotype followed in kindreds from di-
verse ethnic backgrounds [3^6] but there remained
considerable debate as to the mode of inheritance
of the disease.
The demonstration that classical Leber’s heredi-
tary optic neuropathy (LHON) is only inherited
through females [7] and the identi¢cation of exclusive
maternal transmission of mitochondrial DNA
(mtDNA) raised the hypothesis that an mtDNA de-
fect might be responsible [8].
2. Mitochondrial DNA mutations in LHON
2.1. Pathogenic mtDNA mutations associated with
LHON
MtDNA involvement in LHON was con¢rmed
when Wallace and colleagues identi¢ed a point mu-
tation in mtDNA in nine out of 11 families with
LHON from Finland and the USA [9]. This muta-
tion, at bp 11 778, produces an amino acid change in
NADH dehydrogenase subunit 4 (ND4) of complex I
of the respiratory chain, and it was present in all
maternally related members of the LHON families,
regardless of whether they were a¡ected or not. Sub-
sequent work has identi¢ed two further mtDNA mu-
tations in LHON patients at bp 3460 in ND1 [10,11]
and bp 14 484 in ND6 [12] of complex I. These three
mutations are thought to be pathogenic (primary)
mutations in LHON. They are found exclusively in
families with LHON and never in control subjects. In
many patients with the 11 778, 3460 and 14 484 mu-
tations, and particularly in their una¡ected relatives,
there is a degree of heteroplasmy in mtDNA from
blood [12^15]. Heteroplasmy is rarely described in
relation to harmless polymorphisms, but is an almost
universal ¢nding in individuals with the mtDNA mu-
tations that are associated with other mitochondrial
encephalomyopathies. In one study of 159 LHON
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families from Europe and Australasia, 153 (97%) car-
ried one of the three pathogenic LHON mutations
[16].
Other mtDNA bp changes, that have not been
demonstrated in controls, have been described in a
small number of cases in which LHON is the pre-
sumed diagnosis. These include changes at bp 5244,
bp 9101, bp 9804, bp 14 482 and bp 14 498 [17^21].
Further evidence is required before the pathogenic
signi¢cance of these base pair changes can be deter-
mined but, in at least some populations, mtDNA
mutations other than the 11 778, 3460 and 14 484
mutations are presumed to be responsible for a sig-
ni¢cant proportion of LHON cases [22].
2.2. ‘Secondary’ mtDNA base pair changes
A number of other mitochondrial DNA substitu-
tions have been described in families with LHON
and some investigators have termed these ‘secondary’
mutations (e.g. see [23]), although they are found in
the normal population. Many of these were ¢rst de-
scribed in families lacking the 11 778 mutation, prior
to the identi¢cation of the 3460 and 14 484 muta-
tions, and it is not known how many of these fam-
ilies have one of these pathogenic LHON mutations.
It has been suggested that these ‘secondary’ muta-
tions cause visual loss when associated with other
‘secondary’ mutations in the same individual. This
hypothesis is di⁄cult to test, given the high degree
of polymorphism seen in mtDNA. Some authors,
however, have suggested that these changes are
merely harmless polymorphisms of mtDNA. This hy-
pothesis is supported by three observations. First,
none have ever been seen in heteroplasmic form.
Second, they occur in combination with pathogenic
LHON mutations [24^26]. Third, when this occurs
they do not alter the phenotype of the disease [24^
26]. Further, it is clear that the frequency of these
base pair changes in some populations may be higher
than previously recognised [27].
2.3. MtDNA haplotype analysis in LHON
A possible role for these ‘secondary’ base pair
changes in the development of visual failure in
LHON has been suggested by haplotype analysis.
A number (including base pair changes at 4216,
4917, 13 708, 15 257 and 15 812) are found in speci¢c
combinations, which have been used to de¢ne hap-
lotype groupings and hence an evolutionary pattern
for mtDNA. Haplotype analysis of patients with
LHON from a number of populations suggests that
the 3460 mutation is distributed randomly among
haplotypes. However, the 14 484 mutation and, to a
lesser extent the 11 778 mutation, occur on one spe-
ci¢c haplotype (termed haplotype J) considerably
more frequently than expected [22,28^30].
A number of explanations for this association have
been advanced. First, the pathogenic LHON muta-
tion may have occurred once early in the evolution
of haplotype J. However, analysis of the evolution of
haplotype J subgroups suggests that this would then
require loss of the pathogenic LHON mutation in
some subgroups. Second, haplotype J may be more
susceptible to mutational events producing the
pathogenic LHON mutation, although there is no
other evidence to support this. Third, it is possible
that haplotype J may increase the probability of an
individual carrying the pathogenic LHON mutation
developing visual failure, thus creating a sampling
error. This explanation requires that some families
who carry the pathogenic LHON mutation should
be asymptomatic (particularly those families without
haplotype J mtDNA) and this is not supported by
available data. In addition, it is clear that in some
cases the 14 484 mutation can be associated with vis-
ual failure in the absence of any of the haplotype J
base pair changes [31]. Further research may clarify
these unresolved issues.
3. Clinical features of LHON associated with
pathogenic mutations
3.1. Male predominance and age at onset
Early series of Caucasian pedigrees reported that
80^90% of a¡ected members were male [32^35], but a
recent study in the UK found that only 73% of ge-
netically proven cases were male [36]. This di¡erence
may re£ect increased recognition of LHON in fe-
males as a result of the identi¢cation of pathogenic
mtDNA mutations, particularly in isolated cases.
The ability to con¢rm the diagnosis of LHON in
atypical cases has also demonstrated that the range
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of age at onset is wider than previously recognised.
Whilst the majority of patients do develop visual loss
in the second and third decades of life and 95% of
patients are a¡ected by the age of 50 years [15], age
at onset can range between the ¢rst and seventh dec-
ades [35^37].
3.2. Visual failure
The visual disturbance in LHON is typically se-
quential with a median inter-eye delay of 8 weeks.
Acuities decline over a period of 4^6 weeks to 6/60 or
less, colour vision is lost early, and visual ¢eld loss
initially consists of an enlarged blind spot that pro-
gresses to involve central vision producing a large
centrocaecal scotoma. Some patients report pain in
an a¡ected eye or on eye movements, and a small
proportion experience Utho¡’s phenomenon [35,36,
38,39].
Fundoscopy classically reveals a circumpapillary
telangiectatic microangiopathy with swelling of the
peripapillary retinal nerve ¢bre layer. Fluorescein an-
giography usually does not show staining or leakage
from the telangiectatic vessels. The combination of
these features is said to be pathognomic of LHON
[40]. A few weeks after the onset of visual loss, small
vessels on the temporal side of the disc become at-
tenuated. Axonal loss continues over several months,
such that frank optic disc pallor is virtually universal
after 6 months [36].
Visual evoked potentials (VEPs) can be normal in
patients with early visual impairment. In more severe
cases, VEPs are reduced in amplitude, delayed or
desynchronised and are generally less prolonged in
latency and smaller than VEPs recorded in patients
with known demyelinating optic neuropathy [41,42].
In patients with severe visual loss of long duration,
VEPs are usually absent.
Abnormalities of colour vision, fundal changes
and atypical VEPs [41^43] have been reported in a
proportion of asymptomatic male and female mem-
bers of families with LHON in whom they may pre-
dict the later development of visual loss [33,43].
These data predate genetic con¢rmation of the diag-
nosis of LHON and further studies are needed to
clarify their signi¢cance.
Computerised tomography (CT) of the brain and
optic nerves is usually normal in LHON, although
distension of the optic nerve sheaths was reported in
one case [44]. Standard magnetic resonance imaging
(MRI) of the optic nerves is normal [45], but scans
using short time inversion recovery (STIR) sequences
show increased signal in the mid and posterior intra-
orbital sections that is thought to represent gliosis
[46]. Two cases studied using fast spin echo (FSE)
showed bright signal in the optic nerve associated
with small optic nerve sheath complexes and absence
of CSF surrounding the nerves [47].
There are no pathological data on patients with
early optic nerve disease. Autopsy studies of patients
with long-standing visual loss show marked neuronal
cell body and axonal degeneration with associated
loss of myelin, mainly involving the retinal ganglion
cell layer, the optic nerves, optic chiasm, optic tracts
and lateral geniculate bodies [48,49].
3.3. Variation in the visual failure associated with
pathogenic LHON mutations
Leber and other early workers recognised that
some patients with LHON have a good visual prog-
nosis [2], and the identi¢cation of pathogenic LHON
mutations has clari¢ed this phenotypic variability.
Large series of patients with each of the three patho-
genic mutations have been studied in the USA
[35,38,39] and in the UK [36].
First, such series show that the incidence of fundal
appearances characteristic of LHON during the
acute phase of visual failure varies between mutation
groups. Thus, the majority (approximately 75%) of
patients with the 11 778 or 3460 mutations examined
during the acute phase of LHON had typical fundal
appearances, but this was true of only a minority
(V40%) of patients with the 14 484 mutation.
Second, although the degree of initial visual loss is
similar between mutation groups, there is clear var-
iation in the ¢nal visual outcome between patients
with the 11 778 and 3460 mutations and patients
with the 14 484 mutation. This is well illustrated by
the UK study [36], which found that the proportions
of patients with ¢nal visual acuities worse than 6/60
in the better eye (classi¢ed as partially blind) were
high (V75%) for the 11 778 and 3460 mutations and
considerably lower (V30%) for the 14 484 mutation.
The degree of visual recovery in patients with the
14 484 mutation is inversely correlated with age, a
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feature that is not seen with the 11 778 or 3460 mu-
tations.
3.4. Additional features
Harding and colleagues reported six females with a
clinical illness indistinguishable from multiple sclero-
sis (MS), as de¢ned by the Poser criteria, occurring
in the context of a family history of LHON and the
demonstration of the 11 778 mutation [50]. In all
cases visual failure was a prominent, early feature
and patients subsequently developed a progressive
or relapsing illness indistinguishable from MS. The
clinical diagnosis of MS was supported by the dem-
onstration of widespread white matter lesions on
MRI, as seen in MS, in the ¢ve patients scanned
and by abnormalities of CSF analysis and evoked
potentials. Two women with LHON and the 11 778
mutation, but without additional signs, had similar
MRI abnormalities.
Other reports of this association in women with
the 11 778 mutation have followed [51,52], and in
UK families 45% of females with LHON and the
11 778 mutation have an MS-like illness [36]. In con-
trast, it has been reported rarely in males [51,53] or
in patients with the 3460 mutation [27], and it has
not been reported in patients with the 14 484 muta-
tion.
Other neurological abnormalities have been de-
scribed in patients with LHON and a pathogenic
mtDNA mutation at 11 778, 3460 or 14 484. In a
series of Finnish patients additional signs included
movement disorders, kyphosis, polyneuropathy, epi-
lepsy, dementia and brain stem involvement [52].
Such additional abnormalities are unusual in other
large series ^ in one series of 72 patients with the
11 778 mutation only ¢ve patients had other disor-
ders (neuropathy, non-speci¢c muscle weakness, and
a previous diagnosis of poliomyelitis) and these were
considered to be coincidental [35]. A case-control
study of UK patients identi¢ed an increased inci-
dence of tremor in patients with LHON, but no oth-
er neurological features were identi¢ed at higher fre-
quency in patients than in controls [54]. There have
been individual case reports of patients with the
11 778 mutation and LHON together with a variety
of additional features [55,56]. Similarly, in large ser-
ies of patients with the 3460 and 14 484 mutations,
additional neurological features were thought to be
coincidental or alcohol related [36,38,39], although
there have been case reports of individuals with addi-
tional neurological features [57,58].
The suggestion that Finnish patients with LHON
and their relatives are at increased risk of cardiac
pre-excitation syndromes [59] has not been supported
by studies of UK, Australian and US families
[36,60,61]. Other ECG abnormalities have been re-
ported in LHON [34,61].
4. Clinical features of LHON-like illness seen in
association with other mtDNA mutations
Other mtDNA mutations are associated with the
development of subacute visual failure and addition-
al prominent neurological features. Members of fam-
ilies who carry the heteroplasmic mtDNA mutation
at bp 14 459 develop a LHON-like illness associated
with dystonia [62,63]. This was ¢rst identi¢ed in an
Hispanic family with clinical manifestations ranging
from normal, through late-onset optic atrophy, to
early-onset dystonia associated with bilateral basal
ganglia degeneration. When the mutation approaches
homoplasmy, the penetrance is high, with 48% of
maternal relatives manifesting childhood-onset dys-
tonia, 10% a LHON-like illness, and 3% visual fail-
ure and dystonia. A Dutch family with a heteroplas-
mic mtDNA mutation at bp 11 696 (together with a
homoplasmic bp change at 14 596) also manifest a
combination of an LHON-like illness and dystonia
[64]. In a large Queensland family with a homoplas-
mic bp 4160 mutation in addition to the 14 484
LHON mutation, nearly half the patients had a se-
vere encephalitic illness in childhood [65,66]. Patients
who recovered had optic atrophy but little additional
residual neurological de¢cit, whilst other cases had
dysarthria, mild spasticity and athetoid movements
of the face and limbs. MRI scans demonstrated bi-
lateral putaminal lesions.
5. Pedigree analyses in LHON
The male predominance and reduced penetrance of
LHON are central di⁄culties in the understanding of
LHON and, in addition, confound accurate predic-
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tions of recurrence risks to relatives of index cases. A
number of pedigree analyses have attempted to ad-
dress these problems.
The hypothesis that inappropriate X-inactivation
in the optic nerve could explain the transmission
pattern of LHON was ¢rst proposed by Bu and Rot-
ter who analysed 31 pedigrees from published series
[67]. They suggested that the development of LHON
in males is consistent with simultaneous inheritance
of an X-linked visual loss susceptibility locus (VLSL)
and a pathogenic mtDNA mutation. The develop-
ment of LHON in females is also consistent with
this model, provided that a female can be a¡ected
either by being homozygous at the X-linked locus
(40%) or by being heterozygous with inappropriate
X-inactivation (60%). The X-linked gene frequency
was proposed to be 0.08 and the estimated pene-
trance in a heterozygous female 0.11. A similar anal-
ysis of 79 Japanese pedigrees with LHON supported
the model of Bu and Rotter, although the predicted
penetrance for a heterozygous female was somewhat
higher [68].
An analysis of 85 UK families with a pathogenic
mtDNA mutation was entirely compatible with the
model of Bu and Rotter [15]. As predicted by the
model, recurrence risks were higher in children of
a¡ected females than in those of una¡ected females.
Most of the families in this study carried the 11 778
mutation and recurrence risks for this mutation are
shown in Table 1. Similar risks were noted for fam-
ilies with the 3460 and 14 484 mutations, but only
small numbers of families were available for study
and con¢dence limits were therefore wide.
The majority of French Canadian LHON families
carry the 14 484 mutation and pedigree analysis of
this group shows some di¡erences [30]. First, the
male:female ratio is higher than that seen with the
3460 and 11 778 mutations. Second, this study found
no di¡erence in the number of a¡ected children born
to a¡ected and una¡ected mothers, contrary to the
predictions of Bu and Rotter. Recurrence risks from
this study are given in Table 1.
6. Proposed explanations for male predominance and
reduced penetrance in LHON
6.1. X-linked visual loss susceptibility locus
Attempts to demonstrate the existence of an X-
linked VLSL have been unsuccessful. Initial studies
of Finnish families showed linkage to DXS7
(zmax = 2.32 at a= 0.00) [69], but analysis of the
same small region of Xp did not con¢rm this ¢nding
in UK, Italian or German families [70,71]. Reanaly-
sis of an expanded Finnish data set, with altered
a¡ected status in some patients, did not show linkage
to DXS7 [72]. A more recent study of UK families
excluded the presence of a single VLSL acting ac-
cording to the model of Bu and Rotter over 169
cM of the X chromosome in families with the
11 778 mutation [73]. Further, a number of studies
have failed to demonstrate unbalanced X-inactiva-
tion in females from LHON pedigrees as required
by the model of an X-linked VLSL [73,74].
These observations do not exclude the existence of
an X-linked VLSL. First, exclusion mapping can be
inaccurate if the analysis model is incorrect [75], and
it is di⁄cult to obtain pedigree data from LHON
families in a way that does not favour large, multi-
generation pedigrees thus biasing data used in for-
mulating the model. A sib-pair study would eliminate
some of the problems inherent in the previous link-
age analyses. Second, the presence of two or more
separate X-linked VLSLs in families with the 11 778
mutation has not been excluded, nor has the possi-
bility that families carrying the 3460 or 14 484 muta-
tions could develop LHON due to such a VLSL.
Third, the absence of unbalanced X-inactivation in
the leucocytes of females with LHON does not ex-
clude its occurrence in the tissues a¡ected by LHON.
Table 1
Recurrence risks to relatives of index case with the 11 778
mutation [15] or the 14 484 mutation [30]
11 778 mutation 14 484 mutation
Sibs
Males 0.25 0.28
Females 0.08 0.05
Sister’s children
Males 0.41 0.30
Females 0.17 0.03
Matrilineal ¢rst cousins
Males 0.30 0.19
Females 0.07 0.04
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Bu and Rotter proposed that the clinical manifesta-
tions of LHON might be dependent on X chromo-
some inactivation of a small number of embryonic
precursor cells for optic nerve tissue. However, there
is evidence that the degree of unbalanced inactivation
in peripheral blood is generally similar to or greater
than that seen in other tissues [76^78].
Thus, an X-linked VLSL in some cases of LHON
cannot be excluded, and the recent demonstration of
an X-linked optic atrophy gene [79] is of some inter-
est in this context.
6.2. Impairment of mitochondrial respiratory chain
activity
The three pathogenic LHON mutations all occur
in genes encoding subunits of complex I of the mi-
tochondrial respiratory chain and a number of stud-
ies have analysed the e¡ects of such mutations on the
activity of the respiratory chain.
The 3460 mutation produces a severe (approxi-
mately 65%) de¢ciency of mitochondrial complex I
(NADH CoQ1 reductase) activity without reduction
in the activity of complexes II, III or IV. This e¡ect
has been documented in platelets [11,80], cultured
lymphocytes [81] and ¢broblasts [82]. Clonal expan-
sion of ¢broblasts from a patient heteroplasmic for
the 3460 mutation produced clones with zero and
100% mutant mtDNA [82]. Complex I activities in
these clones were normal in the zero percent mutant
clones and 65% de¢cient in the 100% mutant clones.
These results con¢rm that the presence of the 3460
mutation is an absolute requirement for the complex
I de¢ciency. However, the construction of cybrids
with varying nuclear backgrounds in association
with the 3460 mutation suggests that the nuclear en-
vironment can strongly in£uence the expression of
the biochemical defect [82].
The 11 778 mutation apparently produces a less
severe de¢ciency of complex I activity. Studies of
respiratory chain function in platelets [83] and cul-
tured lymphocytes [81] did not show any reduction in
complex I activity as determined spectrophotometri-
cally. A small reduction (approximately 25%) in
platelet complex I activity was observed when non-
smoking patients were compared to non-smoking
controls [80]. However, the rate of electron transport
through the respiratory chain is reduced and this has
led to suggestions that the association of complex I
with other components of the respiratory chain may
be impaired [81]. The construction of cybrids con-
taining mitochondria with either wild type or mutant
11 778 mtDNA has con¢rmed a small reduction in
complex I activity and a more marked reduction in
complex I-linked mitochondrial respiration [84,85].
The 14 484 mutation has been less well studied. No
mitochondrial respiratory chain dysfunction was
found in ¢broblasts [86] but a moderate reduction
of complex I activity has been demonstrated in leu-
cocytes [87]. The demonstration of a severe complex
I de¢ciency in platelet mitochondria from the
Queensland family with LHON and dystonia who
carry the 14 484 mutation (see above) is complicated
by the presence of additional mtDNA mutations [88].
The complex I de¢ciency associated with the
pathogenic LHON mutations is identical in both af-
fected and una¡ected members of LHON pedigrees.
On the available evidence, it is therefore di⁄cult to
propose a direct link between complex I de¢ciency
and the development of visual failure. One interest-
ing observation is that comparatively small amounts
of wild type mtDNA can correct some of the bio-
chemical defect [89], suggesting that small variations
in the proportions of wild type mtDNA in a¡ected
tissues might in£uence the development of LHON.
The e¡ects of pathogenic LHON mutations have
also been studied in vivo using phosphorus magnetic
resonance spectroscopy (MRS). The 11 778 mutation
produces a marked impairment of brain and skeletal
muscle mitochondrial ATP production [83,90,91]
which is similar in degree to the in vitro reduction
of the rate of oxidation of NADH-linked substrates
seen with this mutation. There is a smaller decrease
in skeletal muscle ATP production (phosphocreatine
resynthesis) with the 14 484 mutation and no reduc-
tion with the 3460 mutation [91]. Once again, the
impairment of respiratory chain function is similar
in a¡ected and una¡ected family members.
6.3. MtDNA heteroplasmy
Some have suggested that mtDNA heteroplasmy
may be a factor determining the penetrance of the
disease. Families have been reported in which a rapid
segregation of mitochondrial genotype towards mu-
tant type homoplasmy in blood of either 11 778
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[92,93] or 3460 [14,94] has been associated with de-
velopment of LHON in later generations. This is a
di⁄cult theory to test as there is some evidence that
the degree of heteroplasmy seen in blood is not the
same as that found in other tissues in patients with
LHON. Thus, a post mortem study of an a¡ected
female with the 11 778 mutation found that her
blood contained 33% mutant DNA whilst optic
nerve and retina contained 95 and 100%, respectively
[95]. However, most patients and their una¡ected
relatives from LHON families have very high
amounts of mutant mtDNA (s 95%) in blood.
With some experimental support [49,96] it is assumed
that, in the majority at least, this is paralleled by
near homoplasmy of mutant DNA in the tissues af-
fected by LHON.
6.4. Environmental factors
A number of ¢ndings suggest that there may be an
environmental precipitant to the development of
LHON. First, there is no evidence of signi¢cant cor-
relation between age of onset in index cases and af-
fected siblings in families with LHON [15]. Only four
pairs of monozygous twins have been reported in
families with LHON [15,34,97,98] and two of these
pairs were discordant (in one case occupational ex-
posure to smoke and fumes was postulated to be the
cause of visual loss in the a¡ected twin). Second,
there is evidence that alcohol and tobacco use may
in£uence the course of LHON. This was ¢rst pro-
posed by Bell [99] and a number of anecdotal reports
note that the proportion of patients with the 3460
and 14 484 mutations who consume alcohol and to-
bacco is unusually high [15,38,39]. A case-control
study suggested that there was no excess alcohol
and tobacco consumption in patients with the
11 778 mutation, but that there was a signi¢cant in-
crease in alcohol and tobacco consumption at age at
onset in patients with the 3460 and 14 484 mutations
in comparison to controls [54]. The mechanism by
which alcohol and tobacco might precipitate visual
failure in patients with the 3460 or 14 484 mutation is
unclear, although the association between tobacco
smoking and reduced complex I activity [100] is in-
teresting in this context. Tobacco-alcohol amblyopia
shares some clinical features with the acute phase of
LHON. Thus, in tobacco-alcohol amblyopia visual
loss is subacute, ¢eld examination characteristically
reveals a centrocaecal scotoma, fundoscopy in the
acute stage may reveal papillary microvascular ab-
normalities which do not leak on £uorescein angiog-
raphy and optic atrophy appears in the later stages
of the disease [101,102]. Two series reported patients
who had pathogenic LHON mutations and had pre-
viously been misdiagnosed as having tobacco-alcohol
amblyopia [36,103]. However, tobacco-alcohol am-
blyopia is clearly not the same disease as LHON
[103] and its pathogenesis is not known.
Because tobacco smoke contains cyanide, Wilson
(1965) suggested that patients with LHON might
have an inborn error of cyanide metabolism [104].
However, studies of the activity of rhodanese (thio-
sulphate sulphurtransferase, which metabolises cya-
nide to thiocyanate) in LHON have been con£icting
[104^107]. There is no evidence of impairment of the
metabolism of potential environmental toxins by cy-
tochrome P450 enzymes in LHON [108].
Other single case reports have postulated that
LHON can be triggered by a variety of metabolic
and toxic precipitants, including diabetes [35,109],
B12 de¢ciency in Crohn’s disease [110], carbon mon-
oxide poisoning [111], and toxin exposure [35]. By
extrapolation from the known e¡ects of B12 de¢-
ciency in the pathogenesis of optic nerve disease
and the possible role of cyanide intoxication, hy-
droxycobalamin has been advocated for the treat-
ment of LHON [112]. There is, however, no evidence
of clinical bene¢t of this therapy in LHON.
6.5. Autoimmunity
An autoimmune aetiology of LHON is supported
by a number of clinical observations. First, the sub-
acute onset in young adult life is unusual for a ge-
netic condition. Second, the optic disc appearance
during the acute phase of LHON is similar to that
seen in a number of in£ammatory diseases [36].
However, there is no leakage of £uorescein on an-
giography [40], which suggests that the vascular en-
dothelium remains intact. Third, some patients with
LHON and optic nerve involvement alone have in-
creased immunoglobulins in their CSF [36]. Finally,
LHON is associated with a MS-like illness in some
patients and MS is thought to have an autoimmune
basis [50].
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Antibodies directed against mitochondrial proteins
have been described in human disease. In a patient
with a pathogenic mtDNA mutation at bp 3243 and
the MELAS phenotype, a speci¢c antibody to a 41
kDa mitochondrial antigen was observed [113]. In
patients with primary biliary cirrhosis (PBC), anti-
mitochondrial antibodies are directed against a het-
erogeneous group of antigens, the most important of
which are subunits of pyruvate dehydrogenase [114].
Although in each of these examples the antibodies
are directed against mitochondrial proteins encoded
by nuclear genes, it is clear from rodent studies that
mtDNA-encoded peptides can restrict the immune
response. The maternally transmitted factor (MTF)
of mice was discovered as a component of an alloan-
tigen that induced slow skin graft rejection and a
vigorous cytotoxic T cell (CTL) response and MTF
is encoded by mtDNA [115].
Some experimental data exist to support a role for
autoimmunity in LHON. Antibodies to tubulin, an
optic nerve protein, are present at high frequency in
patients with LHON and their una¡ected maternal
relatives and at low frequency in healthy controls
and patients with ischaemic or compressive optic
neuropathies [116]. There is no association between
LHON and major histocompatibility complex class I
or class II genotypes [117,118].
7. Conclusions
Subacute, sequential visual failure is part of the
phenotype seen in association with a number of
mtDNA mutations. In families with the 14 459 or
11 696 mutations, additional neurological features
are prominent and may be the sole manifestation in
some a¡ected individuals (often termed ‘Leber’s-
plus’). In families with the 11 778, 3460 or 14 484
mutations, visual failure is the dominant feature
and additional features are uncommon (‘Leber’s he-
reditary optic neuropathy’).
Although patients with the 11 778, 3460 or 14 484
mutations are sometimes considered to have the
same disease, an expanding body of evidence sug-
gests that there are marked di¡erences in the mani-
festations of these three pathogenic mutations. For
example, patients with the 14 484 mutation show dif-
ferences in acute fundoscopic appearances and ¢nal
visual outcome in comparison to the 11 778 and 3460
mutation groups. Pedigree analyses delineate varia-
tion in sex ratios and in recurrence risks between the
14 484 and 11 778 mutation groups. In vitro bio-
chemical data on complex I activity and MRS studies
of mitochondrial ATP production show clear di¡er-
ences between mutation groups. Such observations
suggest that the mechanisms underlying the develop-
ment of visual failure may di¡er between patients
carrying each of the pathogenic LHON mutations.
Whilst a number of hypotheses have been pro-
posed, none satisfactorily explain the male predom-
inance and reduced penetrance seen in families with
LHON. The majority of LHON families carry the
11 778 mutation. Although pedigree analyses of these
11 778 families closely ¢t a model of an X-linked
VLSL precipitating visual failure, there is no exper-
imental evidence to support this model. Biochemical
data cannot, at present, show di¡erences between
a¡ected and una¡ected family members. There is
no clear evidence to support a central role for
mtDNA heteroplasmy in the development of visual
failure but analysis of this hypothesis is hampered by
the limited availability of a¡ected tissues (presumed
to include optic nerve and retinal ganglion cells) for
study. Exposure to alcohol and tobacco does not
appear to precipitate visual failure in patients with
the 11778 mutation.
Smaller numbers of patients carry the 3460 and
14 484 mutations and thus experimental data is
more limited. Pedigree analysis of families carrying
the 14 484 mutation provides evidence against an X-
linked VLSL acting according to one proposed mod-
el but this has not been excluded in either mutation
group. Biochemical data shows a marked complex I
de¢cit for the 3460 mutation but con£icting results
for the 14 484 mutation. Anecdotal evidence and one
case-control study suggests a role for alcohol and
tobacco exposure in the development of visual failure
in both the 3460 and 14 484 mutation groups.
This review has outlined some of the clinical and
experimental data in LHON. These data suggest dif-
ferences between the phenotype associated with each
of the three mtDNA mutations which may re£ect
variation in disease mechanisms, although there is
no conclusive evidence to support such a contention.
Further study will elucidate the means by which
these mtDNA mutations lead to the common end-
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point of subacute visual failure described by Theo-
dore Leber.
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